Michael Gilvarry

Michael leads the acute ischemic stroke R&D portfolio as General Manager of the CERENOVUS Neuro Technology Centre (Galway Ireland). Prior to the Johnson & Johnson acquisition of Neuravi, Michael was Vice President of R&D and Technical Operations where he led the development and manufacture of the EMBOTRAP® II Revascularization Device. In Neuravi, he was the founder of the Neuro Thromboembolic Initiative (NTI) through which he led many international research projects in collaboration with Universities and Hospitals in the field of acute ischemic stroke. 

Michael has worked in the medical device industry for 20 years and is a named inventor on over 60 US patents, granted or pending. He holds a BSc in Mechanical Engineering and MSc in Engineering Science from NUI, Galway.

 

The stroke industry is united by a common goal, to develop effective solutions and provide access to treatment which prevents people dying or living a life of dependency because of stroke. World Stroke Day today is a pertinent reminder as to why we work tirelessly, to develop these solutions and deliver the right care so that every 6 seconds a life does not have to be lost to stroke 1 , as is the situation today. Let’s be under no illusion, this is a big task, requiring unwavering commitment and collaboration. Stroke is too big of a challenge for anyone to tackle alone. However, through remarkable partnerships, stroke care has benefitted from some incredible advancements since World Stroke Day was established back in 2006. Perhaps once of the most notable advancements was in the late 1990’s with the introduction of the first recognised treatment for stroke, the ‘clot buster’ Tissue Plasminogen Activator (TPA) which worked to the goal of dissolving the blood clot - and it is still widely used today. Some 20 years after that, everything really changed when mechanical thrombectomy was proven as the most significant advancement in the history of stroke treatment, showing improved outcomes when used together with TPA. It is through collaboration and partnerships that our understanding of and dealing with blood clots has improved enormously and informing advancements in mechanical thrombectomy, whereby clots are removed from the main arteries supplying the brain with blood. However, we are not there yet since stroke is still a global leading cause of death and disability, which means our work is therefore far from done. My opinion is that ischemic stroke is a battle against blood clots, the main cause of ischemic stroke and accounting for 87% of all cases 2 . As in all battles, how do...